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ASAI PENABIRAN CELUSAN TINGGI DALAM FORMAT 384-TELAGA 
UNTUK PENGENALPASTIAN EJEN ANTI-TRIPANOSOMAL TERHADAP 
TRYPANOSOMA BRUCEI RHODESIENSE DAN  
MOD PENGAJIAN KEMATIAN SEL 
 
ABSTRAK 
Dalam usaha untuk mempercepatkan penemuan ubat bagi rawatan 
Tripanosomiasis Afrika Manusia (“Human African Trypanosomiasis”, HAT), adalah 
menjadi keperluan untuk mempunyai satu asai yang mudah dan sensitif dalam 
mengenalpasti “hits” positif berasaskan penabiran celusan tinggi (“high-throughput 
screening”, HTS) seluruh sel. Dalam kajian ini, asai HTS telah dibangunkan dalam 
format 384-telaga dengan membandingkan penggunaan plat cerah dan plat hitam. 
Keteguhan dan kebolehulangan asai yang ditentukan dalam keadaan optimum bagi 
plat 384-telaga adalah bersesuaian untuk asai HTS termasuk peratusan pekali variasi 
4.68% dan 4.74%, nisbah isyarat-kepada-latar belakang 12.75 dan 12.07 dan faktor Z’ 
0.79 dan 0.82 bagi plat telaga 384 cerah dan hitam, masing-masing. Kepekatan akhir 
0.30% dimetil sulfoxide adalah optimum dalam cerakin HTS bagi kedua-dua jenis 
plat. Tiada perbezaan aktiviti yang signifikan dilihat apabila menggunakan ubat 
rujukan pentamidine dan melarsoprol bagi kedua-dua jenis plat. Oleh itu, plat cerah 
384-telaga adalah sesuai untuk digunakan dalam kaedah HTS untuk mengenalpasti 
sebatian yang baharu terhadap Trypanosoma brucei rhodesiense. Sebanyak 1,333 
tumbuh-tumbuhan yang dikutip dari hutan di Malaysia telah diuji dan didapati 
sejumlah enam pokok mempunyai potensi aktiviti anti-tripanosomal. Ekstrak 
tumbuhan tersebut mempunyai nilai IC50 kurang daripada 1.56 μg/mL dengan indeks 
pemilihan (“selectivity index”, SI) melebihi 100. Ujian selanjutnya terhadap T. b. 
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rhodesiense membawa kepada pemilihan Senna spectabilis (IP 117; nama tempatan: 
Kasia Kuning) untuk pengasingan sebatian aktif secara bioasai-berpandu terhadap 
spesies penyebab HAT ini. Dua alkaloid piperidin yang dikenalpasti sebagai (+)-
spectaline (1) dan iso-6-spectaline (2) telah diasingkan daripada daun S. spectabilis 
yang masing-masing mempunyai nilai IC50 0.41 dan 0.71 µM tanpa kesan toksik 
pada sel L6 dengan nilai SI 134.92 dan 123.74. Sebatian 1 dan 2 boleh dianggap 
sebagai calon yang berpotensi untuk penemuan awal ubat bagi HAT. Lanjutan 
daripada itu, perubahan dalam ultrastruktur tripanosom yang disebabkan oleh kedua-
dua sebatian tersebut yang membawa kepada kematian sel teraturcara (“programmed 
cell death”, PCD) telah dikenalpasti dengan menggunakan mikroskop elektron. 
Perubahan ini termasuk jumlah pembahagian sel tripanosom yang luar biasa, kedutan 
pada permukaan tripanosom, kinetoplas yang tidak teratur, pembengkakan 
mitokondria dan pembentukan autofagosom. Penemuan ini membuktikan bahawa 
kematian sel secara autofagik mungkin berlaku dalam T. b. rhodesiense. Tambahan 
pula, pembentukan vakuol autofagik dan kerosakan mitokondria seperti dilihat dalam 
mikroskop elektron telah dibuktikan melalui pelabelan monodansylcadaverine dan 
MitoTracker Red. Menariknya, tripanosom yang dirawat dengan sebatian 1 dan 2 
pada kepekatan tinggi (IC90) selepas 72 jam menunjukkan sebatian tersebut juga 
menyebabkan PCD apoptosis awal, termasuk pendedahan fosfatidilserina, kehilangan 
potensi membran mitokondria dan pengaktifan caspases. Mengambil kira semua ini 
secara bersama, penemuan ini juga menunjukkan potensi sebatian 1 dan 2 sebagai 
kemoterapi semula jadi yang mungkin mewujudkan komunikasi silang di antara 
autofagi dan apoptosis dalam T. b. rhodesiense. Kajian ini melaporkan buat kali 
pertama penemuan kesan penghambat, aspek ultrastruktur dan selular sebatian ini 
terhadap T. b. rhodesiense.  
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HIGH-THROUGHPUT SCREENING ASSAY IN 384-WELL FORMAT FOR 
THE IDENTIFICATION OF ANTI-TRYPANOSOMAL AGENTS AGAINST 
TRYPANOSOMA BRUCEI RHODESIENSE AND  
MODE OF CELL DEATH STUDY 
 
ABSTRACT 
In order to accelerate the discovery of novel leads for the treatment of Human 
African Trypanosomiasis (HAT), it is necessary to have a simple and sensitive assay 
to identify positive hits by whole cell viability based high-throughput screening 
(HTS). In this study, the HTS assay was developed in 384-well format using clear 
plate and black plate, for comparison. Assay robustness and reproducibility were 
determined under the optimized conditions in 384-well plate was well tolerated in the 
HTS assay, including percentage of coefficient of variation of 4.68% and 4.74%, 
signal-to-background ratio of 12.75 and 12.07, and Z’ factor of 0.79 and 0.82 in 
clear- and black-384-well plate, respectively. Final concentration of 0.30% dimethyl 
sulfoxide was well tolerated in the HTS assay in both types of plate. No significant 
differences were observed for reference drugs pentamidine and melarsoprol used in 
the two plate format. Therefore, clear 384-well plate was suitable for use in the HTS 
campaign for the identification of new compounds against Trypanosoma brucei 
rhodesiense. A total of 1,333 plants collected from Malaysian forest were tested 
using the HTS system developed and six plants were found to have potent anti-
trypanosomal activity. These plants extract have an IC50 value less than 1.56 µg/mL 
with associated selectivity indices (SI) greater than 100. Further testing against T. b. 
rhodesiense led to the selection of Senna spectabilis (IP 117; local name: “Kasia 
Kuning”) for further bioassay-guided isolation against the causative species of HAT. 
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Two known piperidine alkaloids (+)-spectaline (1) and iso-6-spectaline (2) were 
isolated from the leaves of S. spectabilis with the greatest IC50 values of 0.41 and 
0.71 µM. Compound 1 and 2 showed no toxic effect on L6 cells with associated SI of 
134.92 and 123.74, respectively which can be considered potential candidates for 
HAT early drug discovery. Subsequently, the ultrastructural alterations in the 
trypanosome induced by these compounds leading to programmed cell death (PCD) 
were characterized using electron microscopy. These alterations include unusual 
amount of trypanosome at dividing state, wrinkling of the trypanosome surface, 
alterations in the kinetoplast, swelling of the mitochondria, and the formation of 
autophagosomes. These findings evidence a possible autophagic cell death in T. b. 
rhodesiense. Furthermore, the formation of autophagic vacuoles and mitochondrial 
damages through monodansylcadaverine and MitoTracker Red labeling agrees with 
the electron microscopy data. Interestingly, trypanosomes treated with high 
concentration (IC90) of compound 1 and 2 after 72 h exhibited significantly induces 
an early apoptosis-like PCD, which includes phosphatidylserine exposure, loss of 
mitochondrial membrane potential and caspases activation. Taken together, these 
findings demonstrated the potential of compound 1 and 2 as a natural 
chemotherapeutic capable of inducing a possible cross-talk between autophagy and 
apoptosis in T. b. rhodesiense. This is the first report on the inhibitory effect, 
ultrastructural and cellular aspects of these two piperidine alkaloids on T. b. 
rhodesiense. 
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CHAPTER 1 
INTRODUCTION 
Human African Trypanosomiasis (HAT) also known as “sleeping sickness” is caused 
by two protozoan parasites, Trypanosoma brucei rhodesiense and Trypanosoma 
brucei gambiense. The trypanosomes are transmitted to human by a bite of the 
infected Glossina spp. (tsetse fly) and multiply extracellular in blood, lymph and 
cerebrospinal fluid. The disease affects about 50 millions of people yearly in 36 sub-
Saharan Africa with an estimated incidence of about 30,000 cases per annum 
(Bowling et al., 2012). The disease has two distinct stages. In the early stage, 
trypanosomes reproduce in hemolymphatic system of the patient whereas in the 
second stage, trypanosomes cross the blood-brain barrier (BBB) to the central 
nervous system (CNS) that results in a coma and finally death of the patient if left 
untreated. Endemics prevalent in rural regions where public health facilities needed 
for an effective treatment are absent. At present, there are only few drugs registered 
for the treatment of HAT, such as suramin, pentamidine, melarsoprol, eflornithine, 
and nifurtimox. Except for eflornithine and nifurtimox, the other drugs were 
developed half century ago (Phillips et al., 2013; Steverding, 2010). Suramin and 
pentamidine are effective against the early stage of HAT whereas the second stage of 
the disease can only be treated with melarsoprol and eflornithine. Drugs for the 
treatment of sleeping sickness are depending on the causative subspecies and their 
ability to cross the BBB. In addition, antigenic variation that protects the 
trypanosome to survive attack by the host’s immune response poses difficulties in 
developing vaccines for the treatment of the disease (Bacchi, 2009).  
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For saving humanity from the neglected diseases, Drugs for Neglected Diseases 
initiative (DNDi) was founded in 2003 by four publicly-funded research institutes 
from Malaysia, India, Kenya, and Brazil, along with the Institut Pasteur and 
Médecins Sans Frontières (MSF). The organization is a not-for-profit research and 
development organization that develops effective, safe and inexpensive medicines 
for neglected diseases that trouble millions people in the poorest countries. DNDi 
focuses on developing new treatments for the most neglected patients suffering from 
diseases such as sleeping sickness, leishmaniasis, chagas disease, paediatric HIV, 
filarial disease, mycetoma, hepatitis C, and malaria. Tackling the burden of neglected 
diseases is not an easy task for any one organization alone. Malaysia being a mega-
diverse country hosts an enormous diversity of plant. A large number of plants found 
in Malaysian rainforests have not yet been studied for their pharmaceutical potentials 
against the parasite. Thus, a special research group was established aimes to 
investigate the pharmaceutical properties of Malaysian plants for their potential for 
the treatment of HAT, one of the most neglected life threatening diseases. In an 
effort to improve the drawback of current treatment of HAT, plant secondary 
metabolites could be a source of new drugs with strong activity and low cytotoxicity 
effect (Alviano et al., 2012). Specifically in the last decade, phytotherapy has 
received great attention in the search for alternatives to chemotherapy in parasitic 
control (Meulas-Serrano et al., 2000). The use of natural products in the treatment of 
various diseases can be traced back in folk medicines. Plants and their derived 
secondary metabolites are an attractive source of lead compounds because they have 
numerous bioactive molecules which may be effective against protozoa. Over the last 
decade, several natural compounds including alkaloids, phenolics, glycosides, and 
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terpenes have been identified to have inhibitory effects on the growth of 
kinetoplastid protozoa (Gehrig and Efferth, 2008). 
In the HAT early drug discovery, resazurin-based viability assay was adopted for 
medium-throughput screening of small extract libraries against T. brucei spp. in 96-
well format (Zahari et al., 2014; Ioset et al., 2009; Raz et al., 1997). With the 
technological advancements in liquid handling robotics, luciferase- (Mackey et al., 
2006) and resazurin-based (Bowling et al., 2012) whole cell viability assay have also 
been used extensively in 96-well format for high-throughout screening (HTS) of 
large set of chemical libraries against T. b. brucei. However, due to the intensive 
labor requirements and costly, this 96-well method is inappropriate for undertaking 
HTS of larger libraries. Therefore, to accelerate the early discovery of novel leads for 
the treatment of HAT, HTS of diverse extracts or compound collections for the 
detection of positive hits by whole cell screening in 384-well format should be 
undertaken. It was hypothesized that the anti-trypanosomal assay in 384-well format 
for HTS whole cell viability screening of T. b. rhodesiense would fulfill HTS criteria.  
1.1  Problem statements 
Since trypanosomes have been recognized as human pathogens, HAT has been 
considered as one of the most devastating health and economic development 
problems in sub-Saharan Africa. Current treatment for HAT are very limited and not 
ideal due to toxicity and impractical administration regimes, a situation that poses 
significant challenges in poorly equipped areas with inadequate medical facilities and 
resources. No other treatments available if the strains of trypanosome have evolved 
resistance to the limited drugs currently used in chemotherapy (Gehrig and Efferth, 
2008). Besides that, except for eflornithine, the mechanisms of action of current 
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drugs still remain poorly understood. Many pharmaceutical companies are unwilling 
to develop drugs for HAT because developing an effective drug needs high costs and 
capital, and knowing that their aim markets are the poorer countries – Asia, Latin 
America and Sub-Saharan Africa (Martyn et al., 2007). All of these factors highlight 
the need to screen and discover new drug leads with high activity and low toxicity 
effect against HAT for future drug development.  
1.2  Justification for the study 
Ninety six-well method is inappropriate for undertaking HTS of large libraries 
because of labor intensive, expensive and time consuming. To accelerate the 
detection of novel leads for the treatment of HAT, the development of a whole cell 
viability assay using human-infective forms of Trypanosoma in 384-well format 
would be very helpful for early drug discovery. Whole cell in vitro HTS screening is 
currently in use to find out novel trypanocidal compounds. However, these HTS 
assays are most often done with one particular non-human pathogenic strain (T. b. 
brucei strain 427). Less often a hit is established in vivo and in vitro on the human 
trypanosome parasites (Reet et al., 2013). Therefore, there is a need to develop an 
HTS assay for detection of viability of human causative agent trypanosome: T. b. 
rhodesiense in 384-well format. The developed HTS assay system would be 
applicable in the discovery of potential HAT drugs and searching for potential 
trypanocidal compounds against the parasite. T. b. rhodesiense was used in screening 
for initial identification of anti-trypanosomal agents because it was also found to be 
more susceptible to standard drugs than other T. brucei subspecies. 
In an attempt to overcome the problems of current treatment of HAT, plant and their 
derived products could be an interesting source of lead compounds with strong 
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activity and low cytotoxicity effect. Several studies have demonstrated the anti-
trypanosomal activity of plant natural products. The toxicity and possible anti-
trypanosomal properties of the plants collected from Malaysia forest shall be 
evaluated through in vitro approach for the identification of anti-trypanosomal agents. 
Elucidation of molecular events of programmed cell death (PCD) in T. b. 
rhodesiense may lead to the discovery of new targets for future chemotherapeutic 
drug development. 
1.3  Aims of the study 
In order to accelerate the discovery of novel leads for the treatment of HAT, it is 
essential to have a simple, robust and inexpensive HTS assay to identify bioactive 
compounds from plant resources targeting T. b. rhodesiense. Therefore, the specific 
objectives of this study include: 
1. To develop anti-trypanosomal assay in 384-well format for high-throughput 
whole cell viability screening of T. b. rhodesiense, 
2. To evaluate the in vitro anti-trypanosomal activity of 1,333 plant extracts by a 
whole cell viability based HTS campaign, 
3. To conduct bioassay-guided isolation of bioactive compounds from selected 
active plants against T. b. rhodesiense, and 
4. To study the cell death actions of T. b. rhodesiense induced by the bioactive 
compounds. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Trypanosoma brucei 
Trypanosoma is a genus of kinetoplastids, a group of unicellular parasitic flagellate 
protozoa. The name is derived from the Greek word trypano which means “borer” 
and soma means “body” owing to their corkscrew-like movement. The scientific 
name was given in 1899 after the discovery of the parasite by Sir David Bruce in 
1894 (Steverding, 2008). Trypanosoma brucei is a protozoan parasite that causes 
African trypanosomiasis, or mostly known as “nagana” in animals and “sleeping 
sickness” in humans. The main reservoir host for T. b. brucei and T. b. rhodesiense is 
cattle or wild bovid, while humans serve as the main reservoir host for T. b. 
gambiense. However, transmission of the disease between animal and animal, animal 
and human, and human and human all take place with T. b. rhodesiense (Keating et 
al., 2015).   
The taxonomic relationships of the three T. brucei have been identified using various 
molecular techniques such as isoenzyme analysis, restriction fragment length 
polymorphism (RFLP) and mini satellite marker analysis (Njiru et al., 2004), enable 
them to be grouped into three subspecies: brucei, gambiense and rhodesiense. The 
first one is not infective to humans even though it is genotypically resembles to the 
other two pathogenic subspecies because of its vulnerability to lysis by trypanosome 
lytic factor-1 (TLF-1) i.e., apolipoprotein L-1 (ApoL-1) molecule, a naturally-
occurring toxins in primates serum that give protection against infection by several 
African trypanosomiasis; while the latter two are typically parasites of humans 
because both appear to be resistance to this serum constituent (Stephensa et al., 2012; 
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Kiefta et al., 2010). Throughout history, African trypanosomiasis has badly 
oppressed the economic and cause losses of US$ 1.5 bilion in agricultural profits 
every year (Faria et al., 2014), where it reduces livestock productivity by up to 50% 
(Ibrahim et al., 2014). 
Most T. brucei are heteroxenous and transmitted through an insect vector (Glossina 
spp.) in the insect’s blood meal. They survive and reproduce extracellular in the 
hemolymphatic system of their mammalian hosts. As they move between insect and 
mammal in their life cycle, the parasites undergo a series of morphological changes. 
The life cycles of T. brucei spp. is initiated in human skin infected with metacyclic 
forms. The trypanosomes then transform to bloodstream forms and spread through 
draining lymph node into the circulatory system (Sternberg, 2004). In addition, the 
bloodstream forms T. brucei are well-known for their variant surface glycoprotein 
(VSG) coats, capable of drawing out both independent B-cell and T-cell dependent 
responses of host adaptive immune system, and cause chronic disease by undergoing 
antigenic variation (Sternberg, 2004). African trypanosome is one of several 
parasties that can cross the BBB (Masocha and Kristensson, 2014). Hence, there is 
an urgent need for the development of new HAT drugs that is active against the late 
stage of the disease. 
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2.1.1  Classification 
The taxonomic classification of T. brucei is as follows (Baral, 2010): 
Kingdom : Excavata 
Phylum : Euglenozoa 
Class  : Kinetoplastida 
Order  : Trypanosomatida 
Family  : Trypanosomatidae 
Subfamily : Trypanozoon 
Genus   : Trypanosoma 
Species : brucei 
Subspecies : brucei 
  gambiense 
  rhodesiense 
2.1.2  Morphology of African trypanosomes 
T. brucei is an unicellular eukaryotic cell of 20 – 30 µm in length (Baral, 2010). It 
has elongated and tapered body shape. Trypanosomes contain all major organelles 
like other eukaryote cells, for example the nucleus, mitochondrion, endoplasmic 
reticulum (ER), Golgi apparatus, and flagellum (Souza, 2008; Overath and Engstler, 
2004). Along with these common structures, the protozoan kinetoplastids are 
characterized by possession of several unique morphological features such as the 
kinetoplast, subpellicular microtubule array and the paraflagellar rod (Figure 2.1). 
The kinetoplast which contains DNA is an integral part of the mitochondrial system 
closely associated with the flagellar basal body (Overath and Engstler, 2004; Parsons 
et al., 2001). The extraordinary molecular configuration of the deoxyribonucleic acid 
(DNA) contained in the kinetoplast was only discovered in the early 1970s (Souza, 
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2008). It is situated near the base of the flagellum and is linked to the flagellum basal 
body by a cytoskeletal structure. The cytoskeleton of kinetoplastids is mainly made 
up of highly polarized microtubules in a highly sub-pellicular array, which runs 
parallel in the inner face of the plasma membrane along the long axis of the cell. This 
defines the cell shape and ensures the cell is intact throughout the cell cycle 
(Matthews, 2005). These microtubules are also resistant to low temperature and 
several drugs used to disrupt the microtubules such as colchicines, colcemid and 
Taxol (Souza, 2008). The first electron microscopic studies revealed the paraflagellar 
rod (lattice structure of proteins) specific to the kinetoplastida presence in the 
flagellum of trypanosomatids due to its localization (Souza, 2008). The flagellum 
originates close to the flagellar pocket and the kinetoplast, and for a large part is 
attached to the main cell body by an undulating membrane. The flagellum consists of 
flagellar axoneme which positions parallel to the paraflagellar rod. The typical 
microtubule axoneme position in the 9+2 arrangement, oriented with the “+” at the 
anterior end and the “–” in the basal body. The primary role of the flagellum is 
locomotion and attachment to the insect vector gut in the procyclic phase. Flagellar 
motility is essential for the bloodstream trypanosome viability (Broadhead et al., 
2006). The mouth of the flagellar pocket is the most posterior part of the 
trypanosome. This is the exit end for the flagellum. The flagellar pocket is the only 
location of exo- and endo-cytosis (Overath and Engstler, 2004). This is very 
important in bloodstream forms because the cell membrane is coated with VSG that 
is synthesized in the Golgi apparatus and transported from the ER to the surface 
(Matthews, 2005). VSG coat protects them from the mammalian host adaptive and 
innate immune response. When the trypanosomes changes into procyclic forms in the 
insect vector midgut the VSG is replaced by a similarly thick coat of procyclins.  
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Figure 2.1: Schematic drawing of the ultrastructure of T. brucei. Adapted from Souza 
(2008).  
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2.1.3  Life cycle of T. brucei 
T. brucei group trypanosomes are obliged to complete their life cycle between 
Glossina spp. (tsetse fly) and mammalian hosts such as humans, cattles and wild 
animals. During the differentiation at each stage of the life cycle, trypanosomes 
frequently change their morphology, metabolism and the major surface proteins. 
Figure 2.2 summarizes the life cycle of T. brucei. The infection begins when 
metacyclic trypanosomes in the saliva of the tsetse fly are injected into skin tissue of 
a mammal during the insect’s blood meal. In some infections, chancre (a local 
inflammatory response to the trypanosomes), happens at the place of inoculation and 
subsides after 4 weeks (Naessens et al., 2003). In the host, metacyclic trypanosomes 
transform into bloodstream trypomastigotes (proliferative long-slender form) and 
spread via the draining lymphatic nodes into the bloodstream. The long-slender 
trypomastigotes are also able to cross the placenta (Brun et al., 2010). The long-
slender forms (dividing form) replicate by binary fission until large numbers build up 
in the blood. The dividing form of trypanosomes transform first into intermediate 
forms and finally short-stumpy forms (non-dividing form) that are infective to tsetse 
fly. These stumpy form trypanosomes stay alive for only two to three days if they are 
not ingested by a tsetse fly in a blood meal as the trypanosomes produce 
prostaglandin D2 (PGD2) which will lead to PCD (Figarella et al., 2005). 
Bloodstream form trypomastigotes are covered by a VSG coat, which protects them 
to survive on the mammalian host’s immune response (Immunoglobulin M and G) 
that will neutralizes the trypanosomes (Wenzler et al., 2016).  
When biting on an infected mammalian host, the tsetse fly is infected with 
bloodstream trypomastigotes. In the tsetse fly midgut, the short-stumpy 
trypanosomes differentiate into procyclic forms (pre-adapted for transmission to the 
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fly). When bloodstream trypomastigotes differentiate into procyclic forms, they shed 
their VSG coat and replace it by a procyclin coat (Wenzler et al., 2016). The 
procyclic forms multiply by binary fission and cross the peritrophic membrane to 
arrive at the proventriculus and become mesocyclic forms and later epimastigote 
forms. Sexual reproduction can happen in salivary glands although it is not 
obligatory in trypanosomes. Sexual reproduction enables quick transmission of vital 
characteristics such as virulence and drug resistance, and genetic exchange (Franco et 
al., 2014). The epimastigotes travel through the esophagus, proboscis, and 
hypopharynx to the salivary gland where they attached to the epithelium of salivary 
gland and differentiate into infectious metacyclic forms (Franco et al., 2014). During 
the insect’s blood meal they are injected into the mammalian host along with the 
saliva. Genetic exchange is common in T. b. rhodesiense, but it is infrequent in T. b. 
gambiense (Koffi et al., 2007). The cycle in the fly takes about 21 days. For most of 
its life cycle in the tse-tse fly vector, the trypanosomes do not need a VSG coat. The 
metacyclic form trypanosomes is the only stage that is infective to mammalian host, 
and it is identified by the presence of the VSG coat that will help the trypanosomes 
to survive in the host (Wenzler et al., 2016; Franco et al., 2014).  
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Figure 2.2: Life cycle of T. brucei. Adapted from Holmes (2003). 
(Holmes, 2013) 
  
Metacyclic 
Epimastigote 
Mesocyclic 
Procyclic 
Long slender 
Short stumpy 
Tsetse Mammal 
Salivary glands 
Midgut 
14 
 
2.2  Human African trypanosomiasis 
The vector-borne parasitic disease, Human African Trypanosomiasis (HAT) or most 
commonly known as sleeping sickness is caused by two sub-species of protozoan 
haemoflagellates T. brucei i.e., T. b. gambiense and T. b. rhodesiense. HAT is 
transmitted to humans by the bite of a tsetse fly (genus Glossina). Sleeping sickness 
is restricted to sub-Saharan Africa where the insect vector resides. HAT is 
recognized as the most Neglected Tropical Disease (NTD) by World Health 
Organization (WHO). The NTD is a group of tropical infections that trouble more 
than 1 billion poor populations of 149 developing countries in Asia, Americas, and 
sub-Saharan Africa. In addition, they contribute a worldwide disease burden 
equivalent to the group of HIV/AIDS with an estimated up to 1 million deaths every 
year (Zahari et al., 2014). In 2000, it was estimated only 0.1% of worldwide funding 
was allocated to drug discovery for tuberculosis and selected tropical diseases (e.g., 
malaria, trypanosomiasis and leishmaniasis), which together account for about 5% of 
the global disease burden (Pink et al., 2005).  
The distribution of HAT throughout 36 countries in sub-Saharan African covering an 
area of 10 million km
2
 between 14° North and 20° South latitude and about 50 
million people are at risk from the disease (Keating et al., 2015; Bacchi, 2009; 
Steverding, 2008; Kennedy, 2006). Figure 2.3 shows the distribution of HAT with 
incidences and risk for travelers. In the early of 19
th
 century, epidemics of HAT were 
reported after major outbreaks. Chemotherapy, vector control and disease 
surveillance have been set up to combat the disease. With less than 5,000 cases 
reported in the entire continent, the disease was almost eliminated in the mid-1960s 
(Franco et al., 2014; Brun et al., 2010). However, the disease resurged in the late 
1990s. In 2006, approximately 50,000 to 70,000 new cases reported in Africa each 
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year, with annual incidence of HAT was estimated as 17,500 new cases (Sykes and 
Avery, 2009a; Sykes and Avery, 2009b). Although the number of reported cases in 
1998 decreased from 37,385 to 3,796 in 2014, which is likely to represent only a 
small number of the true cases being reported, many remain unreported and thus 
untreated, owing to the limited access to the isolated regions and lack of health 
provision (Jones and Avery, 2015; Faria et al., 2014). The disease affects mainly 
poor nations and communities living in remote countryside areas of Africa. People 
also risk becoming infected if they travel through countries where the insect fector is 
prevalent. 
T. b. gambiense is responsible for a chronic infection, widespread in 24 countries in 
west and central Africa, contributes for more than 95% of reported cases of sleeping 
sickness (Reet et al., 2013). A person can be infected for up to a year or more 
without major signs and symptoms of the disease. When more obvious symptoms 
appear, the patient is usually in a late stage of the disease where the CNS is affected 
(Ioset et al., 2009). In contrast to T. b. gambiense, T. b. rhodesiense causes an acute 
infection, common in 13 countries in eastern and southern Africa (Barrett et al., 
2007). Nowadays, this form accounts for less than 5% of reported cases (Faria et al., 
2014). First signs and symptoms are observed a few weeks or months after infection. 
The disease develops rapidly and invades the CNS (Ioset et al., 2009). Ultimately, 
without treatment, HAT is fatal. There is another form of trypanosomiasis which is 
caused by Trypanosoma cruzi and transmitted by triatome bug. The disease is known 
as American trypanosomiasis or Chagas disease happens mainly in Latin America 
(Njiru et al., 2004; Barrett et al., 2003).  
Sleeping sickness has two distinct stages. The early stage or haemolymphatic phase, 
the trypanosomes multiply in the blood and lymphatic system. The symptoms of this 
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stage are itching, fever, headaches, and joints pain (Sykes and Avery, 2009b). In the 
late stage or neurological phase, the trypanosomes crossed the BBB into the spinal 
fluid, infesting the CNS including the brain, causes severe neurologic symptoms and 
changes in behavior, confusion, poor coordination, difficulties with speech, and 
finally disturbance of sleep (somnolescent state), giving the disease its name (Sykes 
and Avery, 2009a). Without treatment of the infection, the patients die within years 
when infected with T. b. gambiense or within months when infected with T. b. 
rhodesiense (Steverding, 2008). 
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Figure 2.3: Distribution of HAT with incidences and risk for travelers. Adapted from 
Brun (2010). 
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2.2.1  Diagnosis of HAT 
To avoid the disease from progressing to the second stage, diagnosis must be made 
as early as possible. Early screening for possible infection involves checking for 
clinical signs (swollen cervical lymph nodes) and neurological signs (extended 
daytime sleeping), or using serological tests such as card agglutination 
trypanosomiasis test (CATT) (Truc et al., 2002). Nevertheless, CATT is only 
available for examining T. b. gambiense infection and is not applicable to 
rhodesiense forms. Diagnosis is easily achieved by microscopic examination of the 
peripheral blood smear in the acute form of the disease caused by T. b. rhodesiense 
(Kennedy, 2006). However, small parasitemia levels can make it difficult to see the 
parasites microscopically. If the parasites have crossed the BBB to initiate 
neurological stage, examining the sample of cerebrospinal fluid via a lumbar 
puncture is required. In the recent development of the new diagnostic methods for 
HAT, much effort has been made in the improvement of the molecular tools to 
overcome the existing limitations of serological and parasitologic diagnostic methods 
(Simarro et al., 2008). Detection of parasites nucleic acids by PCR-based detection 
of infection from the unique genes for both T. b. gambiense (TgsGP gene) and T. b. 
rhodesiense (SRA gene) (Radwanska et al., 2002a; Radwanska et al., 2002b; 
Welburn et al., 2001), molecular dipstick tests allow easier reading of the PCR 
results (Deborggraeve et al., 2006), and the loop-mediated isothermal amplication, 
which is highly sensitive, specific and easy diagnostic assay for the detection of 
parasites in the T. brucei group (Kuboki et al., 2003) become useful as a more 
sensitive approach. 
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2.2.2  Treatment of HAT 
As developing effective drugs requires high costs and resources, most 
pharmaceutical companies are unwilling to develop drugs for this disease (Martyn et 
al., 2007). Drugs are the only main control strategy for HAT because there are no 
vaccines available in the market. However, HAT chemotherapy relies upon a limited 
number of drugs, have associated toxicity effects or impractical administration 
regimes (Sykes and Avery, 2009b). The drugs for treating sleeping sickness are 
depending on the causative subspecies and stage of the disease. In general, if the 
disease is identified earlier, it is curable if treatment is given quickly. The drugs used 
in the HAT treatment of early stage generally safer and easier to administer, usually 
requires several injections. Treatment becomes much more violent when the parasites 
have crossed the BBB. Toxic arsenic drug such as melarsoprol is used to kill the 
parasites. Drugs used in treating late stage of HAT have complex regimen and 
difficult to apply, normally in the form of a series of intravenous infusions for few 
weeks. In addition, the assessment of post-treatment requires follow up of the patient 
for up to 2 years and involves laboratory tests of cerebrospinal fluid obtained through 
lumbar puncture because the parasites may stay viable and reproduce the disease 
months after treatment. 
Currently there are few drugs approved for the treatment of HAT such as 
pentamidine, suramin, melarsoprol, and eflornithine (Figure 2.4). Table 2.1 
summarizes the drug therapy in HAT. The drugs are distributed free of charge to 
disease prevalent countries. The other drugs were discovered before 1950s except for 
eflornithine  (Phillips et al., 2013; Steverding, 2010). Main issues with drug 
treatment include poor efficacy, adverse side-effect and the chemotherapy treatment 
is complicated. First stage of disease is only treatable with suramin and pentamidine, 
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whereas melarsoprol (useful against T. b. rhodesiense and T. b. gambiense) and 
eflornithine (only active against T. b. gambiense) are only effective against the 
second stage of disease. Melarsoprol is an arsenic derivative and toxic to be used 
because it causes reactive encephalopathy in up to 10% of treated patients, in which 
half of these patients die from this harmful reaction (Bowling et al., 2012). It is 
currently used as front-line treatment for the rhodesiense form, and as alternative 
therapy for the gambiense form. Meanwhile, there has also been a spread of 
resistance to melarsoprol in trypanosomes found in central Africa (Abdel-Sattar et al., 
2008).  There are also increasing reports of treatment failures, particularly with 
melarsoprol (Hoet et al., 2004). Although eflornithine is safer than melarsoprol 
however, it needs several intravenous infusions per day, which needs extra costs.  
In addition, the development of vaccine for the treatment of the disease is difficult 
because of the antigenic variation that protects the parasite to survive attack by the 
host’s immune system (Bacchi, 2009). Furthermore, the mechanisms of action of 
these drugs still uncertain except for eflornithine, which selectively inhibits 
polyamine biosynthesis pathway (ornithine decarboxylase) in the parasite (Barrett et 
al., 2011). A drug registered for the treatment of Chagas disease i.e., Nifurtimox was 
introduced in 2009 in the WHO’s List of Essential Medicines (Faria et al., 2014), and 
is currently suggested as front-line treatment for the gambiense form after efficacy 
and safety statistics provided by clinical trials. The nifurtimox-eflornithine 
combination therapy (NECT) is being used as an alternative therapy for melarsoprol-
refractory late stage disease (Barrett et al., 2007). The NECT reduces the number of 
intravenous perfusions with eflornithine and the time of treatment (Jones et al., 2013). 
However, NECT has not been studied for T. b. rhodesiense and thus not applicable to 
rhodesiense form.   
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Figure 2.4: Chemical structure of registered drugs used in the treatment of HAT. 
  
 
Table 2.1: Summary of drug therapy in HAT. 
 
  
Disease Front-line therapy Alternative therapy 
Early stage of T. b. gambiense Pentamidine Suramin 
Early stage of T. b. rhodesiense Suramin None 
Late stage of T. b. gambiense Eflornithine Nifurtimox-
eflornithine 
Late stage of T. b. rhodesiense Melarsoprol None 
Pentamidine Melarsoprol 
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2.3  High-throughput screening in anti-trypanosomal drug discovery 
Whole cell in vitro HTS is a well-established approach for drug discovery programs 
in neglected disease area for some times and is now in use to search for new 
trypanocidal candidates against large compound libraries. In addition, whole cell-
based assays have been successful in resulting in development of drugs for parasitic 
disease in general (Pink et al., 2005). Hence, HTS is a main consideration for HAT 
drug discovery programs. Initially the assays were carried out in 96-well plates but 
with the current technology advancement there are also 1,586-well plates available. 
Typical HTS programs can perform 10,000 assays in a day, while some laboratories 
with ultra high-throughput screening (UHTS) have potential to screen up to 100,000 
compounds per day. The whole cell based screening assays are highly 
physiologically relevant because whole cells instead of a specific target are used as 
screening models. In addition, the whole cell based assay only need a simple 
pathogen viability readout (Faria et al., 2014). Therefore, this approach has the 
potential of identifying new leads and drug targets with novel modes of action.  
For determination of trypanosomes cellular viability, few assay formats have been 
adopted to screen T. brucei sp. via counting 
3
H-hypoxanthine incorporation, nuclear 
staining techniques, flow cytofluorometry, and measurement of culture pH (Sykes 
and Avery, 2009b; Kaminsky and Brun, 1993). The resazurin-based assay or most 
commonly known as Alamar Blue™ (commercially available solution) assay is very 
cost-effective and is a good non-radioactive alternative to the other conventional 
assay. Resazurin was initially used in 1950s to measure the viability of sperm and to 
evaluate contaminants in biological fluids and milk by colorimetry (ÓBrien et al., 
2000). A viability assay in 96-well format, which utilizes the dye Alamar Blue™, has 
been widely reported in the literature for T. brucei sp. (Merschjohann and Steverding, 
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2006; Raz et al., 1997). It has been shown to have great potential for the 
determination of drug sensitivities of African trypanosomes in vitro because it is 
non-toxic to trypanosomes (Raz et al., 1997). Resazurin-based assay involves only a 
single step of preparation. Cell lysis, washing or extraction procedures normally are 
not required (Mackey et al., 2006; Onyango et al., 2000; Raz et al., 1997). The cell 
viability assay by resazurin is based on the principle of reduction of the non-
fluorescent reagent (resazurin) to a fluorescent compound (resorufin) by the 
intracellular reducing environment of living cells over time (Munshi et al., 2014). It 
has been proposed that the reduction of resazurin are part of the glycolytic pathway 
in bloodstream trypanosomes because they rely on glycolytic pathway for energy 
production (Raz et al., 1997). 
In general, after 72 h treatment with compounds, the cell viability of bloodstream 
form trypanosomes from in vitro or in vivo cultures is evaluated using either 
colorimetric, radioactive, fluorometric, or luminescent detection. For example, 
viability assays based on ATP-reduction such as luciferase- and resazurin-based 
whole cell viability assays have been used extensively in 96- and 384-well format for 
high-throughput compound screening of T. brucei spp. owing to their sensitive, easy 
and quick readout (Sykes and Avery, 2009a; Sykes and Avery, 2009b; Mackey et al., 
2006). The latter was used to screen 87,296 compounds against T. b. brucei 
bloodstream form strain 427 in 384-well format with 205 compounds showed greater 
activity. Further testing against T. b. rhodesiense in 96-well format resulting in 6 hits 
from 5 new chemical classes with anti-proliferative activity confirmed (Sykes et al., 
2012).  
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2.3.1 HTS assays formats: 96-, 384- and 1536-well formats 
For many years, HTS assays have been carried out in the typical 96-well microplate. 
The recent objective of most companies is to surpass this format to lower volume and 
higher density formats (e.g., 384- and 1536-well microplates). The advantages of 
using 384- and 1536-well microplates are increased throughput and lower volume, 
which requires lower cost. Rather than increase in throughput, cost-effective is the 
main reason for many HTS researchers to move to 384- and 1536-well microplates. 
The common features of a 96-well plate consist of column 1 – 12 (12 columns) and 
row A – H (8 rows). In comparison with 384- and 1536-well formats, each individual 
well of the 96-well plate contain 4- and 16-subwells in 384- and 1536-well plate, 
respectively. Hence, these plates are subdivided into column 1 – 24 (24 columns) and 
row A – P (16 rows) in a 384-well plate, and column 1 – 48 (48 columns) and row A 
– Z and A – F (32 rows) in a 1536-well plate. With reference to the 96-well plate, the 
384-well plate has four quadrants (1A, 2A, 1B, 2B), whereas the 1536-well plate has 
sixteen quadrants i.e., 1A – 4A, 1B – 4B, 1C – 4C, 1D – 4D corresponding to well 
1A of the 96-well plate (Figure 2.5). When the 96-channel pipetting head of the 
liquid handler interacts with different plate formats, one stroke is needed within a 96-
well plate. In contrast to the 96-well plate, four strokes are needed when a 384-well 
plate is used, each one corresponding to one of four quadrants. Furthermore, when a 
1536-well plate is used, sixteen strokes are needed. Therefore, four full 96-well 
plates is needed to fill an empty 384-well plate and sixteen full 96-well plates is 
required to occupied one whole 1536-well plate. In order to restore the actual 
replicates in the wells of the different plate formats compared to 96-well format, 
samples in at least four wells in 384-well plate and sixteen wells in 1536-well plate 
have to be harvested and counted (Pira et al., 2012). 
